Fact CheckerSign in

NCT07412041Recruiting

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

Source: ClinicalTrials.gov · Last updated 5 Aug 2026

Brief summary (registry, in English)

The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
2 Feb 2026
Start date
22 Jan 2026
Primary completion date
30 Mar 2027
Lead sponsor
Dana-Farber Cancer Institute
Diseases
Lung cancer
NCT number
NCT07412041

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 22 Jan 2026 to the primary completion date, 30 Mar 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).

Other illness

  • Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.

Lab values

  • Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.

Other

  • Patients who are morbidly obese (BMI\>40 kg/m2) or Anorexic (BMI\<17 kg/m2).
  • Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

Who the study is looking for

  • Age ≥18 years at time of diagnosis; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
  • Histologically diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.
  • Patient's treatment plan is to receive neoadjuvant therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.
  • Ability to follow directions and complete questionnaires in English and/or Spanish.
  • Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.
  • Willing to travel to DFCI for necessary data collection.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Dana-Farber Cancer Institute
Coordinator of this site? Confirm its status
BostonUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.